Summit Therapeutics (SMMT) Receivables - Net (2017 - 2022)

Summit Therapeutics (SMMT) has 6 years of Receivables - Net data on file, last reported at $349000.0 in Q4 2022.

• Quarterly Receivables - Net fell 76.16% year-over-year to $349000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $349000.0 (down 76.16% YoY) and the FY2022 annual result came in at $349000.0, down 76.16% from the prior year.
• Receivables - Net grew to $349000.0 in Q4 2022, from $140000.0 in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $17.3 million in Q1 2019 to a low of $140000.0 in Q3 2022.
• A 5-year average of $5.7 million and a median of $1.9 million in 2021 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2018 — Receivables - Net soared 1072.16% — and 2020, when it plunged 96.83%.
• Tracing SMMT's Receivables - Net over 5 years: stood at $14.9 million in 2018, then sank by 30.16% to $10.4 million in 2019, then tumbled by 96.83% to $331000.0 in 2020, then surged by 342.3% to $1.5 million in 2021, then plunged by 76.16% to $349000.0 in 2022.
• The last three Receivables - Net figures came in at $349000.0 (Q4 2022), $140000.0 (Q3 2022), and $238000.0 (Q2 2022), per Business Quant data.